| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5503139 | Journal of the Neurological Sciences | 2016 | 5 Pages |
Abstract
MMF is a good first-line treatment option for NMOSD and AZA remains a valuable first-line drug if its side effects are tolerable while CTX can be a treatment option for patients who cannot tolerate AZA and MMF.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Ageing
Authors
Yan Xu, Qian Wang, Hai-tao Ren, Lin Qiao, Yao Zhang, Yun-Yun Fei, Yan Zhao, Li-ying Cui,